Atara Biotherapeutics (ATRA) EBIAT (2022 - 2025)
Historic EBIAT for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$4.3 million.
- Atara Biotherapeutics' EBIAT rose 8035.97% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.4 million, marking a year-over-year increase of 11757.36%. This contributed to the annual value of -$85.4 million for FY2024, which is 6907.1% up from last year.
- According to the latest figures from Q3 2025, Atara Biotherapeutics' EBIAT is -$4.3 million, which was up 8035.97% from $2.4 million recorded in Q2 2025.
- Atara Biotherapeutics' 5-year EBIAT high stood at $38.0 million for Q1 2025, and its period low was -$88.1 million during Q1 2022.
- In the last 4 years, Atara Biotherapeutics' EBIAT had a median value of -$31.8 million in 2024 and averaged -$36.9 million.
- As far as peak fluctuations go, Atara Biotherapeutics' EBIAT plummeted by 48507.53% in 2023, and later skyrocketed by 21970.9% in 2025.
- Quarter analysis of 4 years shows Atara Biotherapeutics' EBIAT stood at -$74.6 million in 2022, then increased by 18.94% to -$60.4 million in 2023, then surged by 79.0% to -$12.7 million in 2024, then skyrocketed by 66.1% to -$4.3 million in 2025.
- Its EBIAT was -$4.3 million in Q3 2025, compared to $2.4 million in Q2 2025 and $38.0 million in Q1 2025.